HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection technology used in its AIMIGo(TM) System. The company received a notice of allowance from the U.S. Patent and Trademark Office informing the company of the key patent, which relates to the initial AI capability in the form of an expert system for the AIMIGo System. The patent, titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment,” outlines a system that combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with a patient’s symptoms and cardiac risk factors, resulting in a cardiac risk score and providing simplified diagnostic information and actionable instructions for the patient. According to the announcement, HeartBeam has developed the personal, portable and easy-to-use VECG solution to support patients and clinicians in evaluating cardiac symptoms. “We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and saved lives. This patent will be followed by an aggressive IP development effort with PatentVest as we refine our algorithms, systems and devices.”
To view the full press release, visit https://ibn.fm/Hids3
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork